ZLY06 

ZLY06 is an orally active dual agonist of peroxisome proliferator-activated receptor (PPAR) δ and γ (PPAR δ: EC₅₀=341 nM; PPAR γ: EC₅₀=237 nM). ZLY06 induces hepatic lipid accumulation by inhibiting the phosphorylation of AKT1, mediating the upregulation of CD36. In addition, ZLY06 significantly improves glucose and lipid metabolism without increasing body weight, and alleviates fatty liver by promoting β-oxidation of fatty acids and inhibiting hepatic lipogenesis^[1][2].

422.47

C₂₅H₂₆O₆

2834727-04-5

CC1=CC(/C=C2OC(C=C(OCC3CC3)C=C4)=C4C\2=O)=CC(C)=C1OC(C)(C)C(O)=O

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Zheng Li, et al. "Discovery of the first-in-class dual PPARδ/γ partial agonist for the treatment of metabolic syndrome." European Journal of Medicinal Chemistry 225 (2021): 113807.  [Content Brief]

  [2]. Xiaotong Cai, et al. "Novel Dual PPAR δ/γ Partial Agonist Induces Hepatic Lipid Accumulation through Direct Binding and Inhibition of AKT1 Phosphorylation, Mediating CD36 Upregulation." Chemical Research in Toxicology (2024).